SCHOTT is to start technology-intensive improvements in Lukácsháza - VIDEO REPORT

SCHOTT is to start technology-intensive improvements in Lukácsháza - VIDEO REPORT

2020. 12. 04.

Schott

25-year-old SCHOTT Hungary, owned by the German Carl Zeiss Foundation, is launching an investment project on its site in Lukácsháza. 16 items of highly-automated, new generation, Industry 4.0 production lines will be put in service in the pharmaceutical glass and packaging material manufacturing unit. This will be financed from EUR 41 million, together with the establishment of a production and service building.

>

SCHOTT Hungary Kft is a key plant in Hungary, producing primary pharmaceutical glass packaging materials. The company started its operation in Lukácsháza 25 years ago, and has been producing high quality packaging materials for the pharmaceutical industry ever since. In the pharmaceutical sector the Hungarian unit is considered to be the largest manufacturing plant of the Mainz-based SCHOTT group, which is solely owned by the Carl Zeiss Foundation.

This investment on the Hungarian site will involve the purchasing of 16 highly automated production lines, which will be equipped with advanced, energy efficient, high speed and highly automated, new generation measuring and IT devices. An appropriate hall will also be built to accommodate the technology.

The hundreds of millions of vials and carpules, which constitute the annual output of these new production lines, will be distributed to all major pharmaceutical companies in Europe, in order to enable the safe use of any vaccine or medicine filled into them. The SCHOTT products will among others store and contain the vaccine against COVID-19.

Sector articles

N
Novartis’ New Regional R&Đ Center To Elevate Hungarian Operation To The Next Level

Swiss-owned Novartis expands its Hungarian presence by adding a regional R&D center. Apart from its core research functions, the facility will play a crucial role in coordinating related activities in several countries.

2023. 05. 05.

Life Sciences #Life Sciences #Novartis #Budapest #R&D #Innovation
N
Egis To Develop Infrastructure With An Eye On More Production And Efficiency

As part of the continuation of a series of large-scale developments since 2019, leading pharmaceutical giant Egis Gyógyszergyár Zrt. now invests EUR 21.1 million in Körmend to install new technology, increase capacity and enhance efficiency. The investment is ...

2022. 06. 17.

Life Sciences #Life Sciences #Egis #Körmend #Pharmaceutical production #EUR 21.1 million
N
BD to Double Syringe Production Capacity in Tatabánya

Becton Dickinson (BD), one of the world’s leading medical technology companies, announced an investment of 210 million dollars that amounts to nearly one-fifth of its global development budget earmarked for the upcoming years. The project, which will create mo...

2022. 03. 01.

Life Sciences #Life Sciences #NEW Jobs 300 #BD #Tatabánya #USD 210 million #Biosciences